Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration. Results of a prospective randomized placebo-controlled clinical trial. Pharmacological Therapy for Macular Degeneration Study Group

BACKGROUND: Interferon alfa-2a has been shown to be effective as an antiangiogenic agent for several systemic human angiogenic disorders and has shown antiangiogenic activity in the laboratory. OBJECTIVE: To evaluate the safety and efficacy of interferon alfa-2a for the treatment of choroidal neovascularization secondary to age-related macular degeneration. METHODS: A randomized, placebo-controlled, parallel, multicenter double-blind trial was performed at 45 ophthalmic centers worldwide. Four hundred eighty-one patients were randomly assigned to 4 treatment groups: placebo or interferon alfa-2a (Roferon-A), 1.5, 3.0, or 6.0 million international units (MIU). Visual acuity testing, clinical examination, fluorescein angiography, and indocyanine green angiography were evaluated, with the primary end point being a comparison of the number of patients who experienced a loss of 3 lines or more of vision at 1 year. RESULTS: At 52 weeks, 40 (38%; 95% confidence interval, 29%-48%) of 105 placebo-treated patients had lost at least 3 lines of vision (with 12% unavailable for follow-up), compared with 142 (50%; 95% confidence interval, 44%-55%) of 286 in the 3 active treatment groups combined. The difference in proportions was not statistically significant. However, a pairwise comparison of these proportions for the placebo group vs the group that received interferon alfa-2a, 6 MIU (with 26% unavailable for follow-up), showed a statistically significant difference in favor of the placebo group (P = .02) and a nearly significant difference for the placebo vs the 1.5-MIU group (P = .05) (with 16% unavailable for follow-up), again favoring the placebo group. The 3-MIU group (with 22% unavailable for follow-up) did not show a statistically significant difference in pairwise comparison (P = .48), suggesting that a dose-response relationship was not evident. CONCLUSION: Interferon alfa-2a provides no benefit as a treatment for choroidal neovascularization secondary to age-related macular degeneration and may be associated with a poorer visual outcome when given at a dose of 6 MIU. However, the absence of a clear dose-response relationship raises the possibility that the observed differences result from chance.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Age-related macular degeneration: diagnosis and management
Cook et al.
Br Med Bull 2008;85:127-149.
ABSTRACT | FULL TEXT  

An Ethical View of the Ranibizumab and Bevacizumab Controversy--Reply
Miller
Arch Ophthalmol 2008;126:286-287.
FULL TEXT  

Uncertain Compassion in Using a Drug Before the Risks and Benefits Are Known
Narayanan and Kuppermann
Arch Ophthalmol 2006;124:1032-1034.
FULL TEXT  

Ocular versus Extraocular Neovascularization: Mirror Images or Vague Resemblances
Campochiaro and the First ARVO/Pfizer Institute Working Group
IOVS 2006;47:462-474.
FULL TEXT  

Accelerated Drug Development Through Combined Phase 2/3 Clinical Trial Design
Cunningham et al.
Arch Ophthalmol 2004;122:1043-1044.
FULL TEXT  

Combretastatin A-4 Phosphate Suppresses Development and Induces Regression of Choroidal Neovascularization
Nambu et al.
IOVS 2003;44:3650-3655.
ABSTRACT | FULL TEXT  

Helping Patients Experience the Emotions of Vision Loss
Fong et al.
Arch Ophthalmol 2003;121:1041-1042.
FULL TEXT  

Severe interferon associated retinopathy
Tu et al.
Br. J. Ophthalmol. 2003;87:247-248.
FULL TEXT  

Macular Translocation With 360{degrees} Retinotomy for Exudative Age-Related Macular Degeneration
Aisenbrey et al.
Arch Ophthalmol 2002;120:451-459.
ABSTRACT | FULL TEXT  

Targeting of Interferon to Choroidal Neovascularization by Use of Dextran and Metal Coordination
Yasukawa et al.
IOVS 2002;43:842-848.
ABSTRACT | FULL TEXT  

Monoclonal Antibody-Mediated Drug Targeting to Choroidal Neovascularization in the Rat
Kamizuru et al.
IOVS 2001;42:2664-2672.
ABSTRACT | FULL TEXT  

Inhibition of Choroidal Neovascularization by Intravenous Injection of Adenoviral Vectors Expressing Secretable Endostatin
Mori et al.
Am. J. Pathol. 2001;159:313-320.
ABSTRACT | FULL TEXT  

Treatment of subfoveal choroidal neovascularisation in age related macular degeneration: focus on clinical application of verteporfin photodynamic therapy
SOUBRANE and BRESSLER
Br. J. Ophthalmol. 2001;85:483-495.
FULL TEXT  

Transpupillary thermotherapy (TTT) for the treatment of choroidal neovascularisation
Newsom et al.
Br. J. Ophthalmol. 2001;85:173-178.
ABSTRACT | FULL TEXT  

New Soft-Tipped Instruments for Foveal Translocation Surgery With 360{degrees} Retinotomy
Ohji et al.
Arch Ophthalmol 2000;118:1422-1424.
ABSTRACT | FULL TEXT  

Extracts from "Clinical Evidence": Age related macular degeneration
Arnold and Sarks
BMJ 2000;321:741-744.
FULL TEXT  

Age-Related Macular Degeneration
Fine et al.
NEJM 2000;342:483-492.
FULL TEXT  

Long term results of radiotherapy for subfoveal choroidal neovascularisation in age related macular degeneration
Chiquet et al.
Br. J. Ophthalmol. 1999;83:923-928.
ABSTRACT | FULL TEXT  

Radiotherapy for isolated occult subfoveal neovascularisation in age related macular degeneration: a pilot study
Donati et al.
Br. J. Ophthalmol. 1999;83:646-651.
ABSTRACT | FULL TEXT  

Alternative therapies in exudative age related macular degeneration
CHONG and BIRD
Br. J. Ophthalmol. 1998;82:1441-1443.
FULL TEXT  

Cytokine Therapy in Eye Disease
Okada
Arch Ophthalmol 1998;116:1514-1516.
FULL TEXT